Drugs / Coagulation factor IX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05662319 Background | Feb 2023 → Mar 2027 expected | hemophilia | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coagulation factor IX | “Coagulation factor IX (ATC code: B02BD04)” NCT05662319 ↗ |
| Route | Intravenous | “Route of administration: Intravenous (IV)” NCT05662319 ↗ |